EGOR V. BATOROV^1,2,*, ALISA D. INESHINA², TATIANA A. ARISTOVA³, VERA V. DENISOVA³, SVETLANA A. SIZIKOVA³, DARIA S. BATOROVA³, GALINA Y. USHAKOVA³, EKATERINA Y. SHEVELA¹, ELENA R. CHERNYKH¹

Oncology Research, Vol.32, No.10, pp. 1575-1587, 2024, DOI:10.32604/or.2024.047893 - 18 September 2024

Abstract Background: Immune checkpoint ligand-receptor interactions appear to be associated with multiple myeloma (MM) progression. Simultaneously, previous studies showed the possibility of PD-1 and TIM-3 expression on T cells upon stimulation with common γ-chain family cytokines in vitro and during homeostatic proliferation. The aim of the present work was to study the impact of homeostatic proliferation on the expansion of certain T cell subsets up-regulating PD-1 and TIM-3 checkpoint molecules. Methods: The expression of CD25, CD122, CD127 common γ-chain cytokine receptors, phosphorylated signal transducer and activator of transcription-5 (pSTAT5) and eomesodermin (EOMES) was comparatively assessed with flow… More >

WEI JIANG¹, MEI ZHOU^2,*

Oncology Research, Vol.32, No.8, pp. 1359-1368, 2024, DOI:10.32604/or.2024.043423 - 17 July 2024

Abstract Multiple myeloma (MM) is a plasma cell malignancy and remains incurable as it lacks effective curative approaches; thus, novel therapeutic strategies are desperately needed. The study aimed to explore the therapeutic role of dihydromyricetin (DHM) in MM and explore its mechanisms. Human MM and normal plasma samples, human MM cell lines, and normal plasma cells were used for in vitro experiments. Cell counting kit-8 (CCK-8), flow cytometry, and trans-well assays were performed for the assessment of cell viability, apoptosis, migration, and invasion, respectively. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to assess the mRNA expression… More > Graphic Abstract

YAN ZHANG, HEYANG ZHANG, JING WANG, XIN WEI, YI QU, FENG XU, LIJUN ZHANG^*

Oncology Research, Vol.32, No.5, pp. 955-963, 2024, DOI:10.32604/or.2023.043922 - 23 April 2024

Abstract Background: Bortezomib results in peripheral neuropathy (PN) in approximately 50% of patients, during multiple myeloma (MM) treatment, a complication known as Bortezomib-induced peripheral neuropathy (BIPN). The drug response varies among individuals. Genetic factor may play an important role in BIPN. Methods: A next-generation sequencing (NGS) panel containing 1659 targets from 233 genes was used to identify risk variants for developing BIPN in 204 MM patients who received bortezomib therapy. mRNA expression of MTHFR and ALDH1A1 in 62 peripheral blood samples was detected by real-time quantitative PCR (RT-qPCR). Serum homocysteine (Hcy) levels were detected in 40 samples… More > Graphic Abstract

QIAN HU, MENGYAO WANG, JINJIN WANG, YALI TAO, TING NIU^*

Oncology Research, Vol.32, No.4, pp. 753-768, 2024, DOI:10.32604/or.2023.043647 - 20 March 2024

Abstract Multiple myeloma (MM) is a hematologic malignancy notorious for its high relapse rate and development of drug resistance, in which cell adhesion-mediated drug resistance plays a critical role. This study integrated four RNA sequencing datasets (CoMMpass, GSE136337, GSE9782, and GSE2658) and focused on analyzing 1706 adhesion-related genes. Rigorous univariate Cox regression analysis identified 18 key prognosis-related genes, including KIF14, TROAP, FLNA, MSN, LGALS1, PECAM1, and ALCAM, which demonstrated the strongest associations with poor overall survival (OS) in MM patients. To comprehensively evaluate the impact of cell adhesion on MM prognosis, an adhesion-related risk score (ARRS)… More >

XIAN ZHANG¹, ZHUANG ZHOU², JUNZHE WANG¹, MENGMENG HAN¹, HAN LIU¹, MEIRONG ZANG¹, JIANNING LIU¹, JIAPEI LU¹, JINQIAO ZHANG¹, GUOCHUAN ZHANG^2,*, LIXIA SUN^1,#,*

BIOCELL, Vol.48, No.2, pp. 303-311, 2024, DOI:10.32604/biocell.2023.046640 - 23 February 2024

Abstract Background: Prognosis of multiple myeloma (MM) patients with extramedullary disease (EMD) remains poor. T cell dysfunction and an immunosuppressive environment have been reported in the bone marrow (BM) of MM patients. However, the immunosuppressive microenvironment and immune checkpoint receptors (ICRs) on CD8 T cells in the EMD tissue of newly diagnosed MM (NDMM) patients have not been thoroughly studied. Methods: We investigated the expression levels of T cell immunoglobulin mucin-domain-containing-3 (TIM-3) and T-cell immunoglobulin and ITIM domain (TIGIT) on CD8 T cells and the expression of their ligands (Galectin-9 and CD155) on myeloma cells in… More > Graphic Abstract

FRANCESCO PETRELLA^*, ENRICO MARIO CASSINA, LIDIA LIBRETTI, EMANUELE PIRONDINI, FEDERICO RAVEGLIA, ANTONIO TUORO

Oncology Research, Vol.32, No.3, pp. 433-437, 2024, DOI:10.32604/or.2023.046497 - 06 February 2024

Abstract The main aim of antineoplastic treatment is to maximize patient benefit by augmenting the drug accumulation within affected organs and tissues, thus incrementing drug effects and, at the same time, reducing the damage of non-involved tissues to cytotoxic agents. Mesenchymal stromal cells (MSC) represent a group of undifferentiated multipotent cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal family cells. During the last year, they have been proposed as natural carriers for the selective release of antitumor drugs to malignant cells, thus optimizing cytotoxic action on cancer cells, while More >

JIE ZHAO^1,#, XUANTAO YANG^2,#, HAIXI ZHANG¹, XUEZHONG GU^1,*

Oncology Research, Vol.32, No.2, pp. 325-337, 2024, DOI:10.32604/or.2023.030770 - 28 December 2023

Abstract Multiple myeloma (MM) is a hematological tumor with high mortality and recurrence rate. Carfilzomib is a new-generation proteasome inhibitor that is used as the first-line therapy for MM. However, the development of drug resistance is a pervasive obstacle to treating MM. Therefore, elucidating the drug resistance mechanisms is conducive to the formulation of novel therapeutic therapies. To elucidate the mechanisms of carfilzomib resistance, we retrieved the GSE78069 microarray dataset containing carfilzomib-resistant LP-1 MM cells and parental MM cells. Differential gene expression analyses revealed major alterations in the major histocompatibility complex (MHC) and cell adhesion molecules.… More >

ALESSANDRO GOZZETTI^*, MONICA BOCCHIA

Oncology Research, Vol.31, No.3, pp. 271-274, 2023, DOI:10.32604/or.2023.028668 - 22 May 2023

Abstract Novel drug availability has increased the depth of response and revolutionised the outcomes of multiple myeloma patients. Minimal residual disease evaluation is a surrogate for progression-free survival and overall survival and has become widely used not-only in clinical trials but also in daily patient management. Bone marrow aspiration is the gold standard for response evaluation, but due to the patchy nature of myeloma, false negatives are possible. Liquid biopsy and blood-based minimal residual disease evaluation consider circulating plasma cells, mass spectrometry or circulating tumour DNA. This approach is less invasive, can provide a more comprehensive More >

R. Kavitha^1,*, N. Viswanathan²

Intelligent Automation & Soft Computing, Vol.33, No.2, pp. 1305-1320, 2022, DOI:10.32604/iasc.2022.022816 - 08 February 2022

Abstract Bone marrow cancer is considered to be the most complex and dangerous disease which results due to an uncontrolled growth of white blood cells called leukocytes. Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) are considered to be important categories of bone cancers, which induces a larger number of cancer cells in the bone marrow, results in preventing the production of healthy blood cells. The advent of Artificial Intelligence, especially machine and deep learning, has expanded humanity’s capacity to analyze and detect these increasingly complex diseases. But, accurate detection of cancer cells and reducing the… More >

Yang Cao^*, Xu Shi^†, Yingmin Liu^‡, Ren Xu^§, Qing Ai^*

Oncology Research, Vol.27, No.1, pp. 117-124, 2019, DOI:10.3727/096504018X15213031799835

Abstract MicroRNA-338-3p (miR-338-3p) has been reported to be a tumor suppressor in multiple cancer types. However, the biological role of miR-338-3p and its underlying mechanism in multiple myeloma (MM) remain unclear. In the present study, we investigated the biological role and potential of miR-338-3p in MM. We found that miR-338-3p was significantly decreased in newly diagnosed and relapsed MM tissues and cell lines. Overexpression of miR-338-3p in MM cells significantly inhibited proliferation and promoted apoptosis, caspase 3, and caspase 8 activity. Bioinformatics algorithm analysis predicted that cyclin-dependent kinase 4 (CDK4) was a direct target of miR-338-3p, More >